Exploration of biguanido-oxovanadium complexes as potent and selective inhibitors of protein tyrosine phosphatases

BioMetals

Volumn 25, Issue 3, 2012, Pages 599-610

  Lu, Liping ^a   Gao, Xiaoli ^a,b   Zhu, Miaoli ^a   Wang, Sulian ^a   Wu, Qiong ^b   Xing, Shu ^b   Fu, Xueqi ^b   Liu, Zhiwei ^c   Guo, Maolin ^d  

^a SHANXI UNIVERSITY   (China)

^b TAIYUAN NORMAL UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

^d UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

Biguanido oxovanadium complexes; Competitive inhibition; Protein tyrosine phosphatases; Selective inhibition

Indexed keywords

ALKALINE PHOSPHATASE; BIGUANIDO OXOVANADIUM COMPLEX; GUANIDINE DERIVATIVE; HEMATOPOIETIC TYROSINE PHOSPHATASE; LIGAND; METFORMIN; MOROXYDINE; PHENFORMIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ARTICLE; COMPETITIVE INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; IC 50;

BIGUANIDES; ENZYME ACTIVATION; ENZYME INHIBITORS; PROTEIN TYROSINE PHOSPHATASES; VANADATES;

EID: 84864935090     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-012-9548-4     Document Type: Article

References (73)

1. Ala PJ, Gonneville L, Hillman M, Becker-Pasha M, Yue EW, Douty B, Wayland B, Polam P, Crawley ML, McLaughlin E, Sparks RB, Glass B, Takvorian A, Combs AP, Burn TC, Hollis GF, Wynn R (2006) Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B. J Biol Chem 281:38013-38021
2. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699-711
3. Andersen JN, Jansen PG, Echwald SM, Mortensen OH, Fukada T, Del Vecchio R, Tonks NK, Moller NP (2004) Agenomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J 18:8-30
4. Arena S, Benvenuti S, Bardelli A (2005) Genetic analysis of the kinome and phosphatome in cancer. Cell Mol Life Sci 62:2092-2099
5. Bishop MM, Lindoy LF, Skelton BW, White A (2001) Proton controlled supramolecular assembly: a comparative structural study of bis(2- guanidinobenzimidazolo)nickel(II) with bis(2-guanidinobenzimidazole)nickel(II) nitrate and 2-guanidinobenzimidazole. Su. Supramol Chem 13:293-301
6. Bishop MM, Lindoy LF, Skelton BW, White AH (2002) Modification of supramolecular motifs: some effects of incorporation of metal complexes into supramolecular arrays. J Chem Soc, Dalton Trans: 377-382
7. Bishop MM, Coles SJ, Lindoy LF, Parkin A (2006) A systematic study of ligand intermolecular interactions in crystals of copper(II) complexes of bidentate guanidino derivatives. Inorg Chim Acta 359:3565-3580
8. Buglyó P, Kiss E, Fábián I, Kiss T, Sanna D, Garribba E, Micera G (2000) Speciation and NMR relaxation studies of VO(IV) complexes with several O-donor containing ligands: oxalate, malonate, maltolate and kojate. Inorg Chim Acta 306:174-183
9. Byon JCH, Kusari AB, Kusari J (1998) Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem 182:101-108
10. Combs AP, Yue EW, Bower M, Ala PJ, Wayland B, Douty B, Takvorian A, Polam P, Wasserman Z, Zhu WY, Crawley ML, Pruitt J, Sparks R, Glass B, Modi D, McLaughlin E, Bostrom L, Li M, Galya L, Blom K, Hillman M, Gonneville L, Reid BG, Wei M, Becker-Pasha M, Klabe R, Huber R, Li YL, Hollis G, Burn TC, Wynn R, Liu P, Metcalf B (2005) Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. J Med Chem 48:6544-6548
11. Crans DC, Smee JJ, Gaidamauskas E, Yang LQ (2004) The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem Rev 104:849-902
12. Dewang PM, Hsu NM, Peng SZ, Li WR (2005) Protein tyrosine phosphatases and their inhibitors. Curr Med Chem 12:1-22
13. Drake PG, Posner BI (1998) Insulin receptor-associated protein tyrosine phosphatase(s): role in insulin action. Mol Cell Biochem 182:79-89
14. Elchebly M (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:1544-1548
15. Ember B, Kamenecka T, LoGrasso P (2008) Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3 alpha 1. Biochem 47:3076-3084
16. Gans P, Sabatini A, VaccaA(1996) Investigation of equilibria in solution. Determination of equilibrium constants with the HYPERQUAD suite of programs. Talanta 43:1739-1753
17. Gao X, Lu L, Zhu M, Yuan C, Ma J, Fu X (2009) Inhibitory activities of some oxovanadium complexes with N-heterocyclic ligands against PTP1B/ALP. Acta Chim Sinica 67:929-936
18. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B, Tsaprailis G, Gresser MJ, Ramachandran C (1997) Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem 272:843-851
19. Igashira-Kamiyama A, Kajiwara T, Konno T, Ito T (2006) Ferromagnetic coupling promoted by k(3)N: k(2)N bridging system. Inorg Chem 45:6460-6466
20. Iversen LF, Andersen HS, Branner S, Mortensen SB, Peters GH, Norris K, Olsen OH, Jeppesen CB, Lundt BF, Ripka W, Moller KB, Moller NP (2000) Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J Biol Chem 275:10300-10307
21. Iversen LF, Moller KB, Pedersen AK, Peters GH, Petersen AS, Andersen HS, Branner S, Mortensen SB, Moller NP (2002) Structure determination of T cell protein-tyrosine phosphatase. J Biol Chem 277:19982-19990
22. Kenner KA, Anyanwu E, Olefsky JM, Kusari J (1996) Proteintyrosine phosphatase 1B is a negative regulator of insulinand insulin-like growth factor-I-stimulated signaling. J Biol Chem 271:19810-19816
23. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20:5479-5489
24. Lever ABP (1984) Inorganic electronic spectroscopy, 2nd edn. Elsevier, Amsterdam, p 385
25. Li M, Ding W, Baruah B, Crans DC, Wang R (2008) Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV). J Inorg Biochem 102:1846-1853
26. Li Y, Lu L, Zhu M, Wang Q, Yuan C, Xing S, Fu X, Mei Y (2011) Potent inhibition of protein tyrosine phosphatases by copper complexes with multi-benzimidazole derivatives. Biometals 24:993-1004
27. Liljebris C, Martinsson J, Tedenborg L, Williams M, Barker E, Duffy JES, Nygren A, James S (2002) Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B). BioorgMed Chem 10:3197-3212
28. Lu LP, Zhu ML (2003) Bis{N0-[(E)-amino(imino)methyl]morp holinocarboximidamido}copper(II). Acta Crystallogr Sect E E59:m1086-m1088
29. Lu L, Zhu M (2011) Metal-based inhibitors of protein tyrosine phosphatases. Anti-Cancer Agents Med Chem 11:164-171
30. Lu LP, Yang P, Qin SD, Zhu ML (2004a) Bis[1,1-dimethylbiguanide( 1-)jN2,N5]copper(II) monohydrate. Acta Crystallogr Sect C C60:m219-m220
31. Lu LP, Zhang HM, Feng SS, Zhu ML (2004b) Two N,N-dimethylbiguanidium salts displaying double hydrogen bonds to the counter-ions. Acta Crystallogr Sect C C60:O740-O743
32. Lu LP, Zhu ML, Yang P (2004c) Cocrystal of the [MnIV(C2H7N5)]34+ ion and biguanidium: a double hydrogen-bond interaction with guanidinium-recognizing anions. Acta Crystallogr Sect C C60:M18-M20
33. Lu L, Wang S, Zhu M, Liu Z, Guo M, Xing S, Fu X (2010) Inhibition protein tyrosine phosphatases by an oxovanadium glutamate complex, Na2[VO(Glu)2(CH3OH)] (Glu = glutamate). Biometals 23:1139-1147
34. Lu L, Yue J, Yuan C, Zhu M, Han H, Liu Z, Guo M (2011) Ternary oxovanadium(IV) complexes with amino acid-Schiff base and polypyridyl derivatives: synthesis, characterization, and protein tyrosine phosphatase 1B inhibition. J Inorg Biochem 105:1323-1328
35. Ma L, Lu L, Zhu M, Wang Q, Gao F, Yuan C, Wu Y, Xing S, Fu X, Mei Y, Gao X (2011a) Dinuclear copper complexes of organic claw: potent inhibition of protein tyrosine phosphatases. J Inorg Biochem 105:1138-1147
36. Ma L, Lu L, Zhu M, Wang Q, Li Y, Xing S, Fu X, Gao Z, Dong Y (2011b) Mononuclear copper(II) complexes with 3,5-substituted-4-salicylidene-amino-3,5- dimethyl-1,2,4-triazole: synthesis, structure and potent inhibition of protein tyrosine phosphatases. Dalton Trans 40:6532-6540
37. Maccari R, Paoli P, Ottana R, Jacomelli M, Ciurleo R, Manao G, Steindl T, Langer T, Vigorita MG, Camici G (2007) 5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 15:5137-5149
38. Marchi A, Marvelli L, Cattabriga M, Rossi R, Neves M, Bertolasi V, Ferretti V (1999) Technetium(V) and rhenium( V) complexes of biguanide derivatives. Crystal structures. J Chem Soc Dalton Trans 12:1937-1944
39. Montalibet J, Skorey KI, Kennedy BP (2005) Protein tyrosine phosphatase: enzymatic assays. Methods 35:2-8
40. Moucharafieh NC, Eller PG, Bertrand JA, Royer DJ (1978) Spectra and structure of tris-bidentate cobalt(III) complexes containing planar ligands. Inorg Chem 17:1220-1228
41. Mustelin T, Tautz L, Page R (2005) Structure of the hematopoietic tyrosine phosphatase (HePTP) catalytic domain: structure of a KIM phosphatase with phosphate bound at the active site. J Mol Biol 354:150-163
42. Na M, Cui L, Min BS, Bae K, Yoo JK, Kim BY, Oh WK, Ahn JS (2006) Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe Koreana. Bioorg Med Chem Lett 16:3273-3276
43. Nxumalo F, Glover NR, Tracey AS (1998) Kinetics and molecular modelling studies of the inhibition of protein tyrosine phosphatases by N,N-dimethylhydroxylamine complexes of vanadium(V). J Biol Inorg Chem 3: 534-542
44. Peters KG, Davis MG, Howard BW, Pokross M, Rastogi V, Diven C, Greis KD, Eby-Wilkens E, Maier M, Evdokimov A, Soper S, Genbauffe F (2003) Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J Inorg Biochem 96:321-330
45. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS (1994) Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269:4596-4604
46. Ray P (1961) Complex compounds of biguanides and guanylureas with metallic elements. Chem Rev 61:313-359
47. Rehder D (2003) Biological and medicinal aspects of vanadium. Inorg Chem Commun 6:604-617
48. Reul BA, Amin SS, Buchet JP, Ongemba LN, Crans DC, Brichard SM (1999) Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br J Pharmacol 126:467-477
49. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806
50. Shechter Y (2003) Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coord Chem Rev 237:3-11
51. Shrestha S, Bhattarai BR, Lee K-H, Cho H (2007) Mono-and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs. Bioorg Med Chem 15:6535-6548
52. Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PCC, Combs AP (2007) Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett 17:736-740
53. Su YL, Lu LP, Li XM, Zhu ML (2005) Bis(biguanidojN, N')copper(II) dihydrate. Acta Crystallogr Sect E E61:m910-m912
54. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C (2009) Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem 103:554-558
55. Wang Q, Lu L, Yuan C, Pei K, Liu Z, Guo M, Zhu M (2010) Potent inhibition of protein tyrosine phosphatase 1B by copper complexes: implications for copper toxicity in biological systems. Chem Commun 46:3547-3549
56. Wang Q, Zhu M, Lu L, Yuan C, Xing S, Fu X (2011) Potent inhibition of protein tyrosine phosphatases by quinquedentate binuclear copper complexes: synthesis, characterization and biological activities. Dalton Trans 40:12926-12934
57. Willsky GR, Goldfine AB, Kostyniak PJ, McNeill JH, Yang LQ, Khan HR, Crans DC (2001) Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium( IV). J Inorg Biochem 85:33-42
58. Winter CL, Lange JS, Davis MG, Gerwe GS, Downs TR, Peters KG, Kasibhatla B (2005) A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats. Exp Biol Med 230:207-216
59. Woo LC, Yuen VG, Thompson KH, McNeill JH, Orvig C (1999) Vanadyl-biguanide complexes as potential synergistic insulin mimics. J Inorg Biochem 76:251-257
60. Xie J, Seto CT (2007) A two stage click-based library of protein tyrosine phosphatase inhibitors. Bioorg Med Chem 15: 458-473
61. Yang J, Liang X, Niu T, Meng W, Zhao Z, Zhou GW (1998) Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J Biol Chem 273:28199-28207
62. Yuan C, Lu L, Gao X, Wu Y, Guo M, Li Y, Fu X, ZhuM(2009) Ternary oxovanadium(IV) complexes of ONO-donor Schiff base and polypyridyl derivatives as protein tyrosine phosphatase inhibitors: synthesis, characterization, and biological activities. J Biol Inorg Chem 14:841-851
63. Yuan C, Lu L, Wu Y, Liu Z, Guo M, Xing S, Fu X, Zhu M (2010) Synthesis, characterization, and protein tyrosine phosphatases inhibition activities of oxovanadium(IV) complexes with Schiff base and polypyridyl derivatives. J Inorg Biochem 104:978-986
64. Yuan C, Zhu M, Wang Q, Lu L, Xing S, Fu X, Jiang Z, Zhang S, Li Z, Li Z, Zhu R, Ma L, Xu L (2012) Potent and selective inhibition of T-cell protein tyrosine phosphatase (TCPTP) by a dinuclear copper(ii) complex. Chem Commun 48: 1153-1155
65. Zhang ZY (2001) Protein tyrosine phosphatases: prospects for therapeutics. Curr Opinion Chem Biol 5:416-423
66. Zhang S, Zhang ZY (2007) PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 12:373-381
67. Zheng LL, Zhang WX, Oin LJ, Leng JD, Lu JX, Tong ML (2007) Isolation of a pentadentate ligand and stepwise synthesis, structures, and magnetic properties of a new family of homo-and heterotrinuclear complexes. Inorg Chem 46:9548-9557
68. Zhu ML, Lu LP, Jin XL, Yang P (2002a) Trichloro(1,1-dimethylbiguanidium- jN3)zinc(II). Acta Crystallogr Sect C C58:m158-m159
69. Zhu ML, Lu LP, Yang P, Jin XL (2002b) Bis(1,1-dimethylbiguanido) copper(II) octahydrate. Acta Crystallogr Sect E E58:m217-m219
70. Zhu ML, Lu LP, Yang P, Jin XL (2002c) Bis(1,1-dimethylbiguanido) nickel(II). Acta Crystallogr Sect E E58:m272-m274
71. Zhu ML, Lu LP, Yang P (2003a) N,N-Dimethylbiguanidium nitrate. Acta Crystallogr Sect E E59:o586-o588
72. Zhu ML, Yang P, Liu LP (2003b) N-Phenethylbiguanidium tetrachlorozincate(II). Acta Crystallogr Sect E E59:m91-m94
73. Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, Xie N, Wilcox D, Jacobson P, Frost L, Kroeger PE, Reilly RM, Koterski S, Opgenorth TJ, Ulrich RG, Crosby S, Butler M, Murray SF, McKay RA, Bhanot S, Monia BP, Jirousek MR (2002) PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA 99:11357-11362